The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy

Summary Follicular lymphoma (FL) is a heterogeneous disease; therefore, reliable prognostic tools are needed to plan treatment strategies. The FL International Prognostic Index (FLIPI) was developed before the rituximab era, while the PRIMA‐PI was built on rituximab chemotherapy. Our objective was t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2020-12, Vol.191 (5), p.738-747
Hauptverfasser:	Kimby, Eva, Lockmer, Sandra, Holte, Harald, Hagberg, Hans, Wahlin, Björn E., Brown, Peter, Østenstad, Bjørn
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Age Factors Aged Aged, 80 and over chemo-free regimen Chemotherapy Clinical trials Disease-Free Survival Female follicular lymphoma Hematology Humans Immunotherapy Interferon Lymphoma Lymphoma, Follicular - drug therapy Lymphoma, Follicular - mortality Male Middle Aged Monoclonal antibodies prognosis Risk Factors Risk groups Rituximab Rituximab - administration & dosage Rituximab - adverse effects Survival Rate Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!